A Trial of the Jejunal Diversion Procedure

NCT ID: NCT02283632

Last Updated: 2016-06-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2016-05-31

Brief Summary

This is a single site trial to assess metabolic effects in subjects after a Jejunal Diversion procedure was performed.

Detailed Description

The Jejunal Diversion procedure is an adaptation of a jejuno-jejunostomy, which is a surgical procedure often used to address a mix of pathological conditions. The safety of the Jejunal Diversion procedure is not in question, but rather understanding the gastrointestinal signalling effects. Up to 25 eligible subjects will be enrolled into the trial. Enrollment will stop once 15 subjects have undergone the Jejunal Diversion procedure

Conditions

Diabetes; Obesity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Jejunal Diversion

all subjects who receive jejunal diversion surgery

Group Type: EXPERIMENTAL

Jejunal Diversion

Intervention Type: PROCEDURE

The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.

Interventions

Jejunal Diversion

The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. 20 to 60 years of age (inclusive) on the date the ICD is signed

2. A BMI ≥ 27 kg/m2 and < 40 kg/m2

3. HbA1c ≥ 8% (63.9 mmol/mol) and ≤ 11% (96.7 mmol/mol)

4. C-peptide ≥ 3 ng/mL (0.999 nmol/L)

5. At least one of the following:

1. Systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg, or on anti-hypertensive medication

2. HDL < 40 mg/dL (1.0344 mmol/L) (men) or < 50 mg/dL (1.293 mmol/L) (women), or on medication for low HDL

3. LDL > 100 mg/dL (2.586 mmol/L), or on medication for high LDL

4. TG ≥ 150 mg/dL (1.694 mmol/L) or on TG lowering medication treatment

5. FPG ≥ 100 mg/dL (5.556 mmol/L) or on medication for hyperglycemia or anti-T2DM

6. Able to comprehend and sign the EC-approved trial ICD

Exclusion Criteria

1. Unable or unwilling to attend follow-up visits and examinations

2. History of drug and/or alcohol abuse within 2 years of Screening Visit

3. Any previous major GI surgery (e.g., any GI surgery with a resection, etc.) Examples of previous GI surgery allowed include: appendectomy, gall bladder surgery, liver biopsies, endoscopic procedures, etc.

4. Scheduled concurrent surgical procedure

5. Women of childbearing potential who are pregnant or lactating at the time of screening, at the time of surgery, or planning to become pregnant during the follow-up period

6. Psychiatric disorders that may affect compliance with the clinical trial, including dementia, active psychosis, severe depression, or history of suicide attempts

7. Any condition which precludes compliance with the trial, including:

1. Inflammatory diseases of the GI tract, including severe intractable esophagitis, gastric ulceration, duodenal ulceration, or specific inflammation such as Crohn's disease or ulcerative colitis that have been active within the past 10 years

2. History of Hepatitis B or C

3. T1DM

4. LADA (confirmed by positive GAD autoantibodies, IAA, and ICA)

5. Immunocompromised such as that resulting from chronic oral steroid use, cancer chemotherapeutic agents, or immune deficiency disorders

8. Screening laboratory tests with any of the following:

1. ALT and/or AST levels ≥ 4 times ULN according to laboratory normal ranges

2. Blood creatinine level ≥ 1.5 times ULN according to laboratory normal ranges

3. BUN level ≥ 1.5 times ULN according to laboratory normal ranges

9. Use of any of the following medications in the past 120 days:

1. Chronic steroid use

2. Prescription or over-the-counter medications or supplements with a primary indication known to cause or assist in weight reduction

10. Use of any of the following medications in the past 60 days:

a. Promotility agents

11. Any other medical condition or finding for which, at the discretion of the PI, the subject should be excluded

12. Participation in any other clinical trial (not to include registries or survey-only studies) within 30 days or 5 half lives of an investigational drug (which ever is longer), of Visit 1 (Screening Visit) and for the duration of the trial

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ethicon Endo-Surgery

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Robin Scamuffa

Role: STUDY_DIRECTOR

Ethicon, Inc.

Locations

OB KlINIKA

Prague, , Czechia

Countries

Czechia

References

Fried M, Dolezalova K, Chambers AP, Fegelman EJ, Scamuffa R, Schwiers ML, Waggoner JR, Haluzik M, Seeley RJ. A novel approach to glycemic control in type 2 diabetes mellitus, partial jejunal diversion: pre-clinical to clinical pathway. BMJ Open Diabetes Res Care. 2017 Sep 1;5(1):e000431. doi: 10.1136/bmjdrc-2017-000431. eCollection 2017.

Reference Type: DERIVED

PMID: 29225893 (View on PubMed)

Other Identifiers

ESC-14-001

Identifier Type: -

Identifier Source: org_study_id